NCT01777321View on ClinicalTrials.gov

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 17, 2013

Primary Completion Date

October 10, 2013

Study Completion Date

November 11, 2014

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes zoster vaccine GSK1437173A

HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.

Trial Locations (1)

812-0025

GSK Investigational Site, Fukuoka